|
[1] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66:115-132.
|
|
[2] LIM KC, CHOW PK, ALLEN JC, et al. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria[J]. Br J Surg, 2012, 99 (12) :1622-1629.
|
|
[3] ZHONG JH, KE Y, WANG YY, et al. Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension[J]. Gut, 2015, 64 (3) :520-521.
|
|
[4] ZHONG JH, KE Y, GONG WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260 (2) :329-340.
|
|
[5] EICHHOERN PJ, CREYGHTON MP, BERNARDS R. Protein phosphatase 2A regulatory subunits and cancer[J]. Biochim Biophys Acta, 2009, 1795 (1) :1-15.
|
|
[6] KAUKO O, IMANISHI SY, KULESSKIY E, et al. Rules for PP2Acontrolled phosphosignalling and drug responses[J]. BioRxiv, 2018.[Epub ahead of print]
|
|
[7] SHI Y. Serine/threonine phosphatases:Mechanism through structure[J]. Cell, 2009, 139:468-484.
|
|
[8] SHOUSE G, de NECOCHEA-CAMPION R, MIRSHAHIDI S, et al. Novel B55alpha-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest[J]. Oncotarget, 2016, 7 (38) :61081-61092.
|
|
[9] O'CONNOR CM, PERL A, LEONAID D, et al. Therapeutic targeting of PP2A[J]. Int J Biochem Cell Biol, 2018, 96:182-193.
|
|
[10] KAUKO O, WESTERMARCK J. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer[J]. Int J Biochem Cell Biol, 2018, 96:157-164.
|
|
[11] NEVIANI P, HARB JG, OAKS JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells[J]. J Clin Invest, 2013, 123 (10) :4144-4157.
|
|
[12] LAINE A, SIHTO H, COME C, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1[J]. Cancer Discov, 2013, 3 (2) :182-197.
|
|
[13] FUKUAWA C, SHIMA H, TANUMA N, et al. Up-regulation of I-2 (PP2A) /SET gene expression in rat primary hepatomas and regenerating livers[J]. Cancer Lett, 2000, 161 (1) :89-95.
|
|
[14] HUNG MH, CHEN YL, CHU PY, et al. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential[J]. Oncogene, 2016, 35 (37) :4891-4902.
|
|
[15] ZHAI B, HU F, JIANG X, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma[J]. Mol Cancer Ther, 2014, 13 (6) :1589-1598.
|
|
[16] TORTI D, TRUSOLINO L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy:Promises and perils[J]. EMBO Mol Med, 2011, 3 (11) :623-636.
|
|
[17] HUANG CY, HUNG MH, SHIH CT, et al. Antagonizing SET augments the effects of radiation therapy in hepatocellular carcinoma through reactivation of PP2A-mediated Akt downregulation[J]. J Pharmacol Exp Ther, 2018, 366 (3) :410-421.
|
|
[18] JUNTTILA MR, PUUSTINEN P, NIEMELA M, et al. CIP2A inhibits PP2A in human malignancies[J]. Cell, 2007, 130 (1) :51-62.
|
|
[19] HUANG P, QIU J, YOU J, et al. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues[J]. Biomarkers, 2012, 17 (5) :422-429.
|
|
[20] YU HC, HUNG MH, CHEN YL, et al. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A[J]. Cell Death Dis, 2014, 5:e1359.
|
|
[21] HE H, WU G, LI W, et al. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis[J]. Diagn Mol Pathol, 2012, 21 (3) :143-149.
|
|
[22] YANG X, QU K, TAO J, et al. Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2018, 495 (2) :1807-1814.
|
|
[23] QU K, XU X, LIU C, et al. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma[J]. Cancer Lett, 2013, 331 (1) :105-114.
|
|
[24] RITORTO MS, BORLAK J. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies[J]. J Proteome Res, 2011, 10 (7) :3012-3030.
|
|
[25] RITORTO MS, HODE H, VOGELl A, et al. Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC[J]. Biol Chem, 2016, 397 (11) :1147-1162.
|
|
[26] LIU L, WANG D, WANG J, et al. The nitric oxide prodrug JS-K induces Ca (2+) -mediated apoptosis in human hepatocellular carcinoma HepG2 cells[J]. J Biochem Mol Toxicol, 2016, 30 (4) :192-199.
|
|
[27] LIU L, HUANG Z, CHEN J, et al. Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells[J].J Cell Biochem, 2018, 119 (8) :6633-6643.
|
|
[28] LIU L, HUANG Z, CHEN J, et al. Protein phosphatase 2A activation mechanism contributes to JS-K induced caspasedependent apoptosis in human hepatocellular carcinoma cells[J]. J Exp Clin Cancer Res, 2018, 37 (1) :142.
|
|
[29] RIGANTI C, GAZZANO E, POLIMENI M, et al. The pentose phosphate pathway:An antioxidant defense and a crossroad in tumor cell fate[J]. Free Radic Biol Med, 2012, 53 (3) :421-436.
|
|
[30] TONG X, ZHAO F, THOMPSON CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells[J].Curr Opin Genet Dev, 2009, 19 (1) :32-37.
|
|
[31] CHIEN W, SUN QY, LEE KL, et al. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer[J]. Mol Oncol, 2015, 9 (4) :889-905.
|
|
[32] WANG CT, CHEN YC, WANG YY, et al. Reduced neuronal expression of ribose-5-phosphate isomerase enhances tolerance to oxidative stress, extends lifespan, and attenuates polyglutamine toxicity in Drosophila[J]. Aging Cell, 2012, 11 (1) :93-103.
|
|
[33] CIOU SC, CHOU YT, LIU YL, et al. Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling[J]. Int J Cancer, 2015, 137 (1) :104-115.
|
|
[34] KABASHIMA T, KAWAGUCHI T, WADZINSKI BE, et al. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver[J]. Proc Natl Acad Sci U S A, 2003, 100 (9) :5107-5112.
|
|
[35] DUNG TD, CHANG HC, BINH TV, et al. Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo[J]. Int J Mol Med, 2012, 29 (6) :1045-1052.
|
|
[36] GEDALY R, GALUPPO R, DAILY MF, et al. Targeting the Wnt/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535[J].PLo S One, 2014, 9 (6) :e99272.
|
|
[37] GILES RH, VAN ES JH, Clevers H. Caught up in a Wnt storm:Wnt signaling in cancer[J]. Biochim Biophys Acta, 2003, 1653 (1) :1-24.
|
|
[38] THOMPSON MD, MONGA SP. WNT/beta-catenin signaling in liver health and disease[J]. Hepatology, 2007, 45 (5) :1298-1305.
|
|
[39] COLNOT S, DECAENS T, NIWA-KAWAKITA M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas[J]. Proc Natl Acad Sci U S A, 2004, 101 (49) :17216-17221.
|
|
[40] WU HC, LAY IS, SHIBU MA, et al. Zanthoxylum avicennae extract enhances GSK-3beta to attenuate beta-catenin via phosphatase 2A to block metastatic effects of HA22T cells and hepatocellular carcinoma xenografted nude mice[J]. Environ Toxicol, 2017, 32 (9) :2133-2143.
|
|
[41] ISMAIL S, MAYAH W, BATTIA HE, et al. Plasma nuclear factor kappa B and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2015, 16 (4) :1657-1663.
|
|
[42] YANG J, FAN GH, WADZINSKI BE, et al. Protein phosphatase 2A interacts with and directly dephosphorylates Rel A[J].J Biol Chem, 2001, 276 (51) :47828-47833.
|
|
[43] SHU G, ZHANG L, JIANG S, et al. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2Adependent mechanism in hepatocellular carcinoma cells:Roles of impairing PP2A/I2PP2A interaction[J]. Oncotarget, 2016, 7 (26) :40285-40296.
|
|
[44] BAEK SH. When signaling kinases meet histones and histone modifiers in the nucleus[J]. Mol Cell, 2011, 42 (3) :274-284.
|
|
[45] ZHU X, LI D, ZHANG Z, et al. Persistent phosphorylation at specific H3 serine residues involved in chemical carcinogeninduced cell transformation[J]. Mol Carcinog, 2017, 56 (5) :1449-1460.
|
|
[46] YANG N, EKANEM NR, SAKYI CA, et al. Hepatocellular carcinoma and microRNA:New perspectives on therapeutics and diagnostics[J]. Adv Drug Deliv Rev, 2015, 81:62-74.
|
|
[47] RUVOLO PP. The Interplay between PP2A and microRNAs in Leukemia[J]. Front Oncol, 2015, 5:43.
|
|
[48] CHENG Z, WANG HZ, LI X, et al. MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma[J]. J Exp Clin Cancer Res, 2015, 34:27.
|
|
[49] ZHUANG Q, ZHOU T, HE C, et al. Protein phosphatase 2AB55delta enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b[J]. J Exp Clin Cancer Res, 2016, 35:67.
|
|
[50] CHRISTEN V, DUONG F, BERNSMEIER C, et al. Inhibition of alpha interferon signaling by hepatitis B virus[J]. J Virol, 2007, 81 (1) :159-165.
|
|
[51] DUONG FH, DILL MT, MATTER MS, et al. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53[J]. Carcinogenesis, 2014, 35 (1) :114-122.
|
|
[52] GONG SJ, FENG XJ, SONG WH, et al. Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma[J]. Cancer Biol Ther, 2016, 17 (2) :151-162.
|
|
[53] DUONG FH, CHRISREN V, LIN S, et al. Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair[J]. Hepatology, 2010, 51 (3) :741-751.
|
|
[54] DUONG FH, FILIPOWICZ M, TRIPODI M, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A[J]. Gastroenterology, 2004, 126 (1) :263-277.
|
|
[55] LAU CC, SUN T, CHING AK, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression[J]. Cancer cell, 2014, 25 (3) :335-349.
|
|
[56] FU QH, ZHANG Q, ZHANG JY, et al. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation[J].Tumour Bio, 2016, 37 (6) :7277-7286.
|
|
[57] XU J, SHEN ZY, CHEN XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology, 2007, 45 (2) :269-276.
|
|
[58] LODOLA F, LAFORENZA U, BONETTI E, et al. Store-operated Ca2+entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients[J]. PLo S One, 2012, 7 (9) :e42541.
|
|
[59] TANG J, GUO YS, ZHANG Y, et al. CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma[J]. Cell Death Differ, 2012, 19 (11) :1779-1790.
|
|
[60] TANG J, GUO YS, YU XL, et al. CD147 reinforces[Ca2+]i oscillations and promotes oncogenic progression in hepatocellular carcinoma[J]. Oncotarget, 2015, 6 (33) :34831-34845.
|
|
[61] GILLIAM DT, MENON V, BRETZ NP, et al. The CD24 surface antigen in neural development and disease[J]. Neurobiol Dis, 2017, 99:133-144.
|
|
[62] WAN X, CHENG C, SHAO Q, et al. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment[J]. Tumour Biol, 2016, 37 (5) :6073-6084.
|
|
[63] LU S, YAO Y, XU G, et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma[J].Cell Death Dis, 2018, 9 (6) :646.
|
|
[64] SANGODKAR J, FARRINGTON CC, MCCLINCH K, et al. All roads lead to PP2A:Exploiting the therapeutic potential of this phosphatase[J]. FEBS J, 2016, 283 (6) :1004-1024.
|
DownLoad: